# US 2002/0058663 A1 · Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058663 A1
- Document ID: US20020058663A1
- Status: Published application
- Kind: A1
- Application number: 09/985,887
- Filed: 2001-11-06
- Published: 2002-05-16
- Earliest claimed: 1999-05-19
- Assignees: NeuroSearch A/S
- Inventors: Thomas Varming; Frank Watjen
- Web page: https://patentgrep.com/patent/US20020058663A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to the use of compounds capable of inhibiting the activity of a proton-gated cation channel in the treatment or aleviation of diseases or disorders associated with, or mediated by a drop in extracellular pH.

## Claims

### Claim 1

Use of a compound capable of inhibiting a mammalian proton-gated cation channel for the manufacture of a medicament for the treatment, prevention or alleviation of a disease, disorder or condition associated with, or mediated by a drop in extracellular pH.

### Claim 2 (depends on 1)

The use according to claim 1, wherein the compound is an isatin derivative represented by the general Formula I
16
or a pharmaceutically acceptable salt thereof,
wherein
R1 represents hydrogen, alkyl, phenyl or benzyl; and
X represents oxygen, or a group of the formula NOR2, wherein R2 represents hydrogen, alkyl, acyl, phenyl or benzyl; and
Y represents a group of the formula N—R4, wherein R4 represents hydrogen, hydroxy or alkyl; and
n is 0 or 1; and
R6 represents phenyl, naphthyl, thienyl, or pyridyl, all of which groups may be substituted one or more times with halogen, CF3, nitro, amino, cyano, hydroxy alkyl, alkoxy or phenyl, or a group of the formula —SO2NR′R″, wherein R′ and R″ independently of each another represents hydrogen or alkyl; and
“A” represents a ring holding of from five to seven atoms, which ring is fused to the benzo-ring at the positions marked “a” and “b”, and formed by one or the following bivalent radicals:
(a) —CH2—CH2—CH2— (b),
(a) —NR12—CH2—CH2— (b),
(a) —CH2—NR12—CH2— (b),
(a) —CH2—CH2—NR12— (b),
(a) —CH2—CH2—CH2—CH2— (b),
(a) —NR12—CH2—CH2—CH2— (b),
(a) —CH2—NR12—CH2—CH2— (b),
(a) —CH2—CH2—NR12—CH2— (b),
(a) —CH2—CH2—CH2—NR12— (b),
(a) —CH2—CH2—CH2—CH2—CH2— (b),
(a) —NR12—CH2—CH2—CH2—CH2— (b),
(a) —CH2—NR12—CH2—CH2—CH2— (b),
(a) —CH2—CH2—NR12—CH2—CH2— (b),
(a) —CH2—CH2—CH2—NR CH2— (b),
(a) —CH2—CH2—CH2—CH2—NR12— (b),
wherein
R12 represents hydrogen, alkyl, alkyl substituted with hydroxy, alkoxy-alkyl, alkoxy-carbonyl-alkyl, alkyl-carbonyl-oxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, phenyl or benzyl, which phenyl or benzyl group is optionally substituted with halogen, CF3, nitro, amino, cyano, hydroxy-alkyl, alkoxy, or a group of the formula —SO2NR′R″, wherein NR′R″ independently of each another represents hydrogen or alkyl.

### Claim 3 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula II
17
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12, X, Y and n have the meanings set forth in claim 1.

### Claim 4 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula III
18
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12 and X have the meanings set forth in claim 1.

### Claim 5 (depends on 4)

The use according to claim 4, wherein the compound is
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-(4-nitrophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-methyloxim;
5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-(4-fluorophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
5-(4-chlorophenyl)-8-methyl-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
5-(2-naphthyl)-8-methyl-6-7-8-9-tetrahydro-1-H-pyrrolo-[3.2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-acetyloxim;
8-methyl-5-(4-(N,N-dimethylsulfamoyl)-phenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime;
8-methyl-5-(4-toluyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-(4-methoxyphenyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3.2-h]-isoquinoline2,3-dione-3-oxim;
8-methyl-5-(3-methoxyphenyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3.2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6-7-8-9-tetrahydro-1-H-pyrrolo-[3.2-h]-isoquinoline-2,3-dione-3-O-2,2-dimethylpropanoyl-oxim;
8-methyl-5-(2-methoxyphenyl)-67-8-9-tetrahydro-1-H-pyrrolo-[3.2-h]-isoquinoline-2,3-dione-3-oxim;
8-benzyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methoxycarbonylmethyl-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime;
8-(2-propynyl)-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime; or
8-cyclopropylmethyl-5-phenyl-6,7,8,9-tetrahydro1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime;
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-O-methyloxim;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula IV
19
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12, X, Y and n have the meanings set forth in claim 1.

### Claim 7 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula V
20
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12 and X have the meanings set forth in claim 1.

### Claim 8 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula VI
21
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12, X, Y and n have the meanings set forth in claim 1.

### Claim 9 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula VII
22
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12 and X have the meanings set forth in claim 1.

### Claim 10 (depends on 9)

The use according to claim 9, wherein the compound is
7-ethyl-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-f]-isoquinoline-2,3-dione-3-oxim; or
5-phenyl-7-methyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo[3,2-f]-isoquinoline-2,3dione-3-oxim;
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula VIII
23
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12, X, Y and n have the meanings set forth in claim 1.

### Claim 12 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula IX
24
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12 and X have the meanings set forth in claim 1.

### Claim 13 (depends on 12)

The use according to claim 12, wherein the compound is
7-methyl-5-phenyl-1-6-7-8-tetrahydrobenzo-[2,1-b:3,4-c]-dipyrrole-2,3-dione-3-oxime;
7-methyl-5-(1-naphthyl)-1-6-7-8-tetrahydrobenzo-[2,1-b:3,4-c]-dipyrrole-2,3-dione-3-oxime; or
7-ethyl-5-phenyl-1-6-7-8-tetrahydrobenzo-[2,1-b:3,4-c]-dipyrrole-2,3-dione-3-oxime;
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula X
25
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, X, Y and n have the meanings set forth in claim 1.

### Claim 15 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula XI
26
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, and X have the meanings set forth in claim 1.

### Claim 16 (depends on 15)

The use according to claim 15, wherein the compound is
5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-naphthalene-2,3-dione-3-oxim; or
5-(4-chlorophenyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-naphthalene-2,3-dione-3oxim;
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula XII
27
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, X, Y and n have the meanings set forth in claim 1.

### Claim 18 (depends on 1, 2)

The use according to claim 2, wherein the compound is represented by the general Formula XIII
28
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, and X have the meanings set forth in claim 1.

### Claim 19 (depends on 1)

The use according to claim 1, in which the compound is N-amidino-3,5-diamino-6-chloropyrazine-2-carboxamide (Amiloride).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The use according to any of claims 1-19, wherein the disease, disorder or condition is associated with reduced blood flow to the brain and other CNS tissue, or associated with instances of a temporary break in blood supply to the brain or to other CNS tissue.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The use according to any of claims 1-19, wherein the disease, disorder or condition is an ischaemic disease, an anoxic episode, an injury to the brain and other parts of the CNS caused by trauma or other injury, a blow to the head, or a spinal injury, a tromboembolic or haemorrhagic stroke, a cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, cerebral trauma, lathyrism, Alzheimer's disease, and Huntington's disease, cerebral ischaemia or cerebral infarction, ischaemic, hypoxic or anoxic brain damage, spinal cord injury, tissue ischaemia and reperfusion injury in a mammal at risk for such damage.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The use according to any of claims 1-21, wherein the proton-gated cation channel is an ASIC1-, ASIC1A-, ASIC1B-, ASIC2-, ASIC2A-, ASIC2B-, ASIC3-, or ASIC-β-channel.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The use according to any of claims 1-22, wherein the compound is used simultaneously with a pharmaceutically effective amount of an AMPA receptor antagonist.

### Claim 24 (depends on 23)

The use according to claim 23, wherein the AMPA receptor antagonising compound is
2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo-(f)-quinoxaline (NBQX);
6,7-dinitroquinoxaline-2,3-dione; or
6-cyano-7-nitroquinoxaline-2,3-dione;
or a pharmaceutically acceptable salt thereof.

### Claim 25

A method for the treatment, prevention or alleviation of a disease, disorder or condition in a subject, including a human, which disease, disorder or condition is associated with, or mediated by a drop in extracellular pH, said method comprising administering to the subject a pharmaceutically effective amount of a compound capable of inhibiting a mammalian proton-gated cation channel.

### Claim 26 (depends on 25)

The method according to claim 25, in which the disease or disorder is a diseases associated with reduced blood flow to the brain and other CNS tissue, or associated with instances of a temporary break in blood supply to the brain or to other CNS tissue.

### Claim 27 (depends on 25)

The method according to claim 25, in which the disease or disorder is an ischaemic disease, an anoxic episode, an injury to the brain and other parts of the CNS caused by trauma or other injury, a blow to the head, or a spinal injury, a tromboembolic or haemorrhagic stroke, a cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, cerebral trauma, lathyrism, Alzheimer's disease, and Huntington's disease, cerebral ischaemia or cerebral infarction, ischaemic, hypoxic or anoxic brain damage, spinal cord injury, tissue ischaemia and reperfusion injury in a mammal at risk for such damage.

### Claim 28 (depends on 25, 26, 27)

The method according to any of claims 25-27, in which the proton-gated cation channel inhibiting compound is an ASIC1-, ASIC1A-, ASIC1B-, ASIC2-, ASIC2A-, ASIC2B-, ASIC3-, or ASIC-β-inhibiting compound.

### Claim 29 (depends on 28)

The method according to claim 28, which method comprises simultaneous administration of a pharmaceutically effective amount of the compound capable of inhibiting a mammalian proton-gated cation channel and a pharmaceutically effective amount of an AMPA receptor antagonist.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the AMPA receptor antagonising compound is
2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo-(f)-quinoxaline (NBQX);
6,7-dinitroquinoxaline-2,3-dione; or
6-cyano-7-nitroquinoxaline-2,3-dione;
or a pharmaceutically acceptable salt thereof.
